ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

ClinicalTrials.gov ID: NCT06846671

Public ClinicalTrials.gov record NCT06846671. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors

Study identification

NCT ID
NCT06846671
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
BeOne Medicines
Industry
Enrollment
250 participants

Conditions and interventions

Interventions

  • BGB-16673 Drug
  • Bendamustine Drug
  • Idelalisib Drug
  • Rituximab Drug
  • Venetoclax Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 9, 2025
Primary completion
May 14, 2028
Completion
Feb 13, 2030
Last update posted
Apr 21, 2026

2025 – 2030

United States locations

U.S. sites
20
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
St Bernards Medical Center Jonesboro Arkansas 72401 Recruiting
UCLA Department of Medicine Hematologyoncology Los Angeles California 90095-3075 Recruiting
Pih Health Whittier Hospital Whittier California 90602 Recruiting
Rocky Mountain Cancer Centers (Williams) Usor Aurora Colorado 80012-5405 Recruiting
Florida Oncology and Hematology Fort Myers Florida 33912 Recruiting
Baptist Md Anderson Cancer Center Jacksonville Florida 32207-8432 Recruiting
Cleveland Clinic Florida Weston Florida 33331-3609 Recruiting
Emory University Winship Cancer Institute Atlanta Georgia 30322-1013 Recruiting
Our Lady of the Lake Hospital Baton Rouge Louisiana 70808-4365 Recruiting
American Oncology Partners of Maryland Pa Bethesda Maryland 20817-7847 Recruiting
Oncology Hematology Associates Springfield Missouri 65807-5288 Recruiting
Oncology Hematology West, Pc Dba Nebraska Cancer Specialists Omaha Nebraska 68130-2042 Recruiting
Memorial Sloan Kettering Cancer Center Mskcc New York New York 10065-6800 Recruiting
Clinical Research Alliance, Inc Westbury New York 11590-5119 Recruiting
University Hospitals Cleveland Ohio 44106-1716 Recruiting
Dayton Physician Network Dayton Ohio 45415 Recruiting
Oncology Associates of Oregon Willamette Valley Cancer Center Eugene Oregon 97401 Recruiting
West Penn Hospital Pittsburgh Pennsylvania 15224 Recruiting
Cancer Care Associates of York York Pennsylvania 17403-5049 Recruiting
Texas Oncology Tyler Tyler Texas 75702-7522 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06846671, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 21, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06846671 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →